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Abstract
Background: Wilson's disease (WD) is a rare inherited disorder that leads to copper
accumulation in the liver, brain, and other organs. WD is prevalent worldwide, with an
occurrence of 1 per 30,000 live births. Currently, there is no gold standard diagnostic
test for WD. The objective of this systematic review is to determine the diagnostic
accuracy for WD of three biochemical tests, namely hepatic copper, 24-hour urinary
copper, and ceruloplasmin using the Leipzig criteria.
Methods: Adhering to PRISMA guidelines, databases including PubMed/MEDLINE,
CINAHL Plus, Web of Science, and Cochrane were searched. Studies that comprised
of confirmed or suspected WD along with normal populations were included with
adult and pediatric group. The sensitivity, specificity, negative predictive value and
positive predictive value were computed using RevMan 5.4.
Results: Nine studies were included. The best practice evidence for 24-hour urinary
copper test ranged from a cutoff value of 0.64–1.6 μmol/24 h (N = 268; sensitivity = 75.6%, specificity = 98.3%). Hepatic copper test was optimally cutoff based on
the ROC curve analysis at 1.2 μmol/g yielding a power of 96.4% sensitivity and 95.4%
specificity (N = 1,150); however, the tried and tested 4 μmol/g cutoff, with 99.4% sensitivity and 96.1% specificity, is more widely accepted. The ceruloplasmin test cutoff
value was found to be ranging from 0.14 to 0.2 g/L (N = 4,281; sensitivity = 77.1%–
99%, specificity = 55.9%–82.8%).
Conclusion: This paper provides a large-scale analysis of current evidence pertaining
to the biochemical diagnosis of WD employing the Leipzig criteria. The laboratory
values are typically based on specific subgroups based on age, ethnicity, and clinical
subgroups. The findings of this systematic review must be used with caution, given
the over- or under-estimation of the index tests.
KEYWORDS

ceruloplasmin, hepatic copper, hepatolenticular degeneration, liver copper, urinary copper,
Wilson's disease
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I NTRO D U C TI O N

suspected WD as assessed by the Leipzig criteria, which was essential for inclusion. Studies that did not use the Leipzig crite-

Wilson's disease (WD) was first described in 1912 by Samuel Wilson

ria and did not define WD were excluded. The three index tests

as an autosomal recessive metabolic disorder occurring due to muta-

were ceruloplasmin, liver copper content, and urinary copper that

tions of the ATP7B gene.1 It is a rare inherited disorder that leads to

were evaluated for diagnosing WD. The cutoff thresholds for each

2

copper accumulation in the liver, brain, and other vital organs. WD is

of the index test are provided in Figure 1. The clinical reference

found worldwide, with an estimated prevalence of 1 per 30,000 live

standard to the diagnosis of WD is outlined in the Leipzig criteria

births across populations,3 although the data obtained by molecular

below.
Two pairs of authors (AS-Z S and HMS-JS) independently ex-

sequencing from the United Kingdom suggest higher prevalence of
4

1 per 7,021 live births. A large proportion of patients are diagnosed

tracted data onto a google spreadsheet, and any discrepancies

between the ages of 5 and 35 years, but it may affect the older pop-

were resolved by active discussion. The data were entered as au-

ulation as well.1,2 At present, there is no gold standard diagnostic

thor and year, participant and methodology, clinical characteris-

test for Wilson's disease, where only the measurements of liver

tics, index test details, the reference standard used in the study,

5

and biases of the included studies. The sensitivity, specificity, pos-

Owing to the nonspecific clinical features of Wilson's disease, the

itive predictive value (PPV), and negative predictive value (NPV)

battery of laboratory and clinical tests for diagnosis is oftentimes

were calculated using ReviewManger 5.4 (RevMan 5.4, Cochrane),

delayed.6 Ultimately, this may affect the clinical outcomes and has

which are tabulated for all three index tests in Tables 1–3 . The

implications for members in the family tree when considering late

data were entered into the software as the number of TP/ par-

copper content are being used to improve the diagnostic accuracy.

or missed diagnosis earlier during the disease course.7,8 With the

ticipants with WD (TP + FN). The higher the sensitivity for a

Leipzig criteria, the shortcoming of no gold standard diagnostic test

particular cutoff, the better the test was considered in correctly

may be overcome by promoting the standardization of diagnosis and

identifying individuals with WD. The specificity was calculated as

9

treatment of disease.

the number of TN/ participants without WD (TN + FP). The higher

The objective of this systematic review is to determine the

the specificity of the cutoff value, the better the diagnostic test in

diagnostic accuracy, that is, sensitivity and specificity of bio-

identifying individuals who do not have WD. PPV is the number

chemical tests, including hepatic copper, 24-h our urinary copper

of TP/ numbers of TP + FP. PPV measures the individuals with

content, and ceruloplasmin. These laboratory markers are ideally

positive tests who have WD. NPV is the number of TN/numbers

tested in suspected patient and control groups. With inconsistent

of TN +FN. NPV measures the number of people with a negative

gold standard testing for the diagnosis of Wilson's disease, the

test result that do not have WD. The methodology encompassed

Leipzig criteria are used as the standard for this investigation. The

a diagnostic analytical technique to determine the diagnostic cut-

key purpose is to scale the benefits of these tests for patients

offs of the biochemical tests.

under an index of suspicion or whether the test should be used
at large.

2

|

3

M ATE R I A L S A N D M E TH O DS

|

R E S U LT S

The PRISMA flowchart is depicted in Figure 2. In total, 13,783 studies were identified from the enlisted databases. On removing 6,436

In accordance with the Preferred Reporting Items for Systematic
10

Reviews and Meta-A nalyses (PRISMA) Statement 2020,

obser-

vational studies (retrospective/prospective cohorts and case con-

duplicates, 7,347 studies were screened. Overall, 21 studies were
retrieved and thereby assessed for eligibility. Finally, 9 studies were
included in this analysis.

trols) that tested the diagnostic accuracy of any or all three index
tests in the context of diagnosing WD were included. Databases
including the following were searched: PubMed/MEDLINE,

3.1 | Characteristics of included studies

CINAHL Plus, Web of Science, and Cochrane. The date of the last
database search was October 20, 2021. There were no language

The characteristics of the included studies are listed in Table 4.

restrictions. A combination of the following keywords was used:

Only 5 of the 9 studies provided data for ceruloplasmin. Overall,

Wilson's disease, Wilson's disease, ceruloplasmin, urinary copper,

while 6 of the 9 studies were case controls, with one each being a

hepatic copper, liver copper, and hepatolenticular degeneration.

cross-sectional, a prospective cohort, and a genetic cohort study,

The studies included participants with confirmed or suspected

they were well-designed and had robust inclusion criteria along

WD and also comprised of normal population and heterozygotes

with a battery of index testing. Individualistic differences of index

in cases where genetic testing was used. In case the study evalu-

tests, patient populations, and evaluations are listed (Table 4). A

ated the index test in the normal population with the Leipzig cri-

proportion of the sample size presented mild hepatic WD, whereas

teria but did not include a WD comparator group, it was omitted.

neurological cases and asymptomatic WD presentations were also

The target population was the pediatric and adult population with

included.

|
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F I G U R E 1 Diagnostic algorithm for Wilson's disease based on the Leipzig score

TA B L E 1 Ceruloplasmin diagnostic accuracy (sensitivity, specificity, PPV, and NPV using 95% CI)
Author (Year)

Threshold

Sensitivity vs. Specificity (95% CI)

PPV vs. NPV (95% CI)

Mak et al. (2008)

0.1 g/L

78.9% (CI: 66.1–88.6) vs. 100% (CI: 97.3–100)

100% (CI: NE) vs. 91.9% (CI: 87.3–94.9)

Nicastro et al. (2010)11

0.1 g/L

65% (CI: 66.1–88.6) vs. 96.6% (CI: 88.1–99.6)

92.9% (CI: 76.6–98.1) vs. 80% (CI: 72.3–86)

15

12

Sezer et al. (2014)

0.2 g/L

77.1% (CI: 59.9–89.6) vs. 65.9% (CI: 49.4–79.9)

65.9% (CI: 54.9–75.4) vs. 77.1% (CI: 63.9–86.6)

Xu et al. (2018)13

0.2 g/L

99% (CI: 97.1–99.8) vs. 80.9% (CI: 79.6–82.2)

29.1% (CI: 27.8–3 0.5) vs. 99.9% (CI: 99.7–100)

Merle et al. (2009)14

0.19 g/L

93.6% (CI: 87.3–97.4) vs. 58.8% (CI: 44.2–72.4)

83.1% (CI: 77.9–87.2) vs. 81% (CI: 66.9–90.1)

Abbreviations: CI, confidence interval; NE, not estimated; NPV, negative predictive value; PPV, positive predictive value.

TA B L E 2 24-hour urinary copper test diagnostic accuracy (sensitivity, specificity, PPV, and NPV using 95% CI)
Author (Year)

Threshold
11

Sensitivity vs. Specificity (95% CI)

PPV vs. NPV (95% CI)

Nicastro et al. (2010)

0.64 μmol/24 h

78.9% (CI: 62.7–90.5) vs. 87.9% (CI: 76.7.1–95)

81.1% (CI: 67.7–89.7) vs. 86.4% (CI: 77.4–92.2)

Nicastro et al. (2010a)11

1.6 μmol/24 h

65.8% (CI: 48.7–8 0.4) vs. 98.3 (CI: 90.8–100)

96.2 (CI: 77.9–99.4) vs. 81.4 (CI: 73.8–87.2)

Lu et al. (2010)16

1.6 μmol/24 h

50% (CI: 29.9–70.1) vs. 97.1% (CI: 89.8–99.6)

86.7% (CI: 61.1–96.4) vs. 83.5% (CI: 77.5–88.2)

Sezer et al. (2014)12

1.6 μmol/24 h

80% (CI: 63.1–91.6) vs. 75.6% (CI: 59.7–87.6)

73.7% (CI: 61.4–83.1) vs. 81.6% (CI: 69.1–86.4)

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.

3.2 | Ceruloplasmin index test

cutoff for the ceruloplasmin index test was determined to be between 0.14 and 0.2 g/L. The studies were well-designed, clearly

Five of the 9 studies evaluated the threshold of ceruloplasmin across

defined WD, and the details of the laboratory cutoffs were con-

4,281 individuals, among which 541 had WD. The cutoffs were de-

ducted using receiver operating characteristic (ROC) curve analysis.

fined by the Leipzig criteria (0.1 g/L and 0.2 g/L; 0.19 g/L) (Mak

It may be noted that ceruloplasmin levels are lower in the neona-

et al., 2008, Nicastro et al.11 2010, Sezer et al.12 2014, Xu et al.13

tal age group; however, the levels rise in women who are currently

2018, Merle et al.14 2009) (Table 1). In these five studies, the optimal

pregnant or taking oral contraception and those undergoing acute

4 of 8
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TA B L E 3 Hepatic copper test diagnostic accuracy (sensitivity, specificity, PPV, and NPV using 95% CI)
Author (Year)

Threshold

Sensitivity vs. Specificity (95% CI)

PPV vs. NPV (95% CI)

>4 μmol/g

88.3% (CI: 75.2–89.7) vs. 98.6% (CI: 96.1–99.7)

96.9% (CI: 91.1–99) vs. 91.9% (CI: 88.3–94.5)

Ferenci et al. (2005a)

>1.2 μmol/g

96.5% (CI: 91.3–99) vs. 95.4% (CI: 91.8–97.8)

91.7% (CI: 85.7–95.3) vs. 98.1% (CI: 95.2–99.3)

Nicastro et al. (2010)11

>4 μmol/g

93.3% (CI = 77.9–99.2) vs. 52.2% (CI = 37–67.1)

56% (CI: 48.1–63.6) vs. 92.3% (CI: 75.4–97.9)

Sezer et al. (2014)

>4 μmol/g

65.7% (CI = 47.8–8 0.9) vs. 75.6% (CI = 59.7–87.6)

69.7% (CI: 56.1–8 0.6) vs. 72.1% (CI: 61.3–8 0.8)

Yang et al. (2015)18

>4 μmol/g

94.4% (CI = 89.9–97.3) vs. 96.8% (CI = 94.7–98.2)

91.8% (CI: 87.2–94.9) vs. 97.8% (CI: 96.1–97.5)

17

Ferenci et al. (2005)

17

12

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.

F I G U R E 2 PRISMA flowchart

inflammation. Nicastro et al.11 (2010) and Sezer et al.12 (2014) con-

which may vary in terms of reference range, precision, and bias.

ducted their studies in the pediatric population; Mak et al.15 (2008)

Therefore, the cutoff values identified as 0.14–0.2 g/L serve as an

and Xu et al.13 (2018) used a mixed pediatric and adult population,

essential method that is paramount when the same sample is run

and Merle et al.14 (2009) only enrolled the adult population. Because

using the same analyte with a different method, but will possibly

ceruloplasmin is synthesized in the liver, the levels are lower in other

lead to different results as seen in the Merle study.14

causes of chronic liver disease, enteropathies, and nephrotic syndrome as compared to WD. Literature suggests that individuals undergoing chelation therapy have lower levels of ceruloplasmin levels;
14

however, Merle et al.

3.3 | 24-Hour urinary copper test

present differing results where 65% of the

sample was on penicillamine therapy but the minute differences

At present, there is limited evidence pertaining to the adult cutoff,

in assay technology may have led to this effect. It is imperative to

with data enlisted by the European Association for the Study of

account for the different methods of the analyte—ceruloplasmin,

the Liver (EASL) of 1.6 μmol/24 h. However, this systematic review

17

The reassessment of the
diagnostic value of 24-hour
urinary copper excretion in
children with Wilson's disease

Diagnostic accuracy of serum
ceruloplasmin in Wilson's
disease: determination of
sensitivity and specificity by
ROC curve analysis among
ATP7B-genotyped subjects

Serum ceruloplasmin oxidase
activity is a sensitive and
highly specific diagnostic
marker for Wilson's disease

Re-evaluation of the diagnostic
criteria for Wilson's disease
in children with mild liver
disease

Is it necessary to re-evaluate
diagnostic criteria for
Wilson's disease in children?

Mak et al. (2008)15

Merle et al. (2009)14

Nicastro et al. (2010)11

Sezer et al. (2014)12

Diagnostic value of quantitative
hepatic copper determination
in patients with Wilson's
disease

Title

Lu et al. (2010)16

Ferenci et al. (2005)

Author (Year)

TA B L E 4 Characteristics of included studies

Case control*

Case control*

Case control*

Case control*

Case control*

Case control*

Study type

Patients with hepatic WD, alternative hepatic
pathologies, or normal controls

Confirmed WD patients either with
asymptomatic family screening or
hepatic etiology, with alternative hepatic
pathologies, or normal controls

Individuals with WD, neurological or hepatic,
with alternative hepatic pathologies, or
normal controls

Individuals with WD of neuropsychiatric,
hepatic, or asymptomatic type, groups with
no diagnosis of hepatic or neurological
deficit, and normal controls

The individuals had unknown hepatic
pathologies

Individuals with WD, of neuropsychiatric,
hepatic, or asymptomatic type, controls
without WD and participants with other
hepatic pathologies

Sample characteristics

Ceruloplasmin by
immunoturbidimetry
Roche Modular;
urine copper with
atomic absorption
spectrophotometry
AA-6701F Shimadzu;
and hepatic copper
by atomic absorption
spectrophotometry
AA-6701F Shimadzu

Hepatic copper with
flame absorption
spectrophotometry;
urine copper using
flame absorption
spectrophotometry;
ceruloplasmin
using radial
immunodiffusion
NOR-Partigen
Behring

Ceruloplasmin
nephelometry Dade
Behring

Ceruloplasmin with
nephelometry
Beckman Coulter
IMMAGE

24-hour urinary copper
was measured by ICP
mass spectrometry

Hepatic copper was
measured by
atomic absorption
spectroscopy

Index laboratory testing

|
(Continues)

Selection bias, non-
randomization bias may
increase the risk of bias or
confounders

Case-control study type
increases the risk of non-
randomization and less
diverse sample set

Sample selection, non-
randomization, and case-
control amplify the risk of
bias

The nature of clinical reference
standards in addition to
non-randomization and low
acceptability of results with
small sample size may lead
to the risk of bias

Non-randomization, selection
bias of the case-control
design may have led to bias

Given the non-randomized
enrollment and
observational nature of the
study, potential biases may
have existed

Biases

SALMAN et al.
5 of 8
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The study had the minimal
risk of bias other than the
relatively less sample size as
compared to a large genetic
cohort study

presents three studies that enlist the 24-hour urinary copper cutoffs of children with WD-associated CLD (Lu et al.16 2010, Nicastro
et al.11 2010, Sezer et al.12 2014) (Table 2). Lu and colleagues utilized
24-hour urinary copper was measured by ICP mass spectrometry
using a Chinese population,16 whereas Nicastro/Sezer and et al.11,12
used an atomic absorption spectroscopy in an Italian and Turkish
population, respectively (Table 2). Both these studies used a clear criterion for diagnosing WD, and there were gender- and age-matched
controls. Wherever differences in cutoffs were present, they may
have occurred due to slight differences in methods and ethnicity.

Direct sequences of the
ATOX1, COMMD1,
and CP genes; direct
DNA sequencing of
the ATP7B gene

The study had the minimal risk
of bias, and the population
was most reflective of
clinical practice
Hepatic copper using
atomic absorption
spectrophotometry
Beijing Purkinje
General Instruments

Beckman Coulter
Immage;
ceruloplasmin using
nephelometry

Index laboratory testing

The cross-sectional study design
leads to increase the risk of
selection bias

SALMAN et al.

Biases
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3.4 | Hepatic copper
On considering the cutoffs for copper, four studies in total were eligible, and differences in age groups, methods, and index test analysis
WD criteria and employed a pediatric and adult population, and adequate laboratory methods were utilized to evaluate hepatic copper
by using atomic absorption spectroscopy.17 The optimal cutoff based
on the ROC curve analysis was 1.2 μmol/g, giving it a power of 96.4%
sensitivity and 95.4% specificity. This is in opposition to the higher
cutoff used in the Leipzig criteria of 4 μmol/g. However, the Leipzig
criteria for hepatic copper were originally based on a sample of 7
individuals with WD as posited by Ferenci and colleagues.17 When
noting the study by Yang and colleagues, which employed a Chinese
Note: *All patients were being tested for WD, and the Leipzig criteria were the standard of reference.

Patients with WD: asymptomatic, hepatic,
neurological/psychiatric, and neurological/
hepatic
Genetic
prospective
cohort
Association of Variants in the CP,
ATOX1, and COMMD1 genes
with Wilson's disease
symptoms in Latvia
Zarina et al. (2019)21

Patients with suspected hepatic WD, family
member of people with confirmed WD,
or those that had alternative hepatic
pathologies
Prospective
cohort
Prospective evaluation of the
diagnostic accuracy of
hepatic copper content, as
determined using the entire
core of a liver biopsy sample
Yang et al. (2015)18

Patients that underwent ceruloplasmin analysis
were eligible to be included, and the tests/
records were noted in a hospital center
Cross-sectional
The optimal threshold of serum
ceruloplasmin in the diagnosis
of Wilson's disease: A large
hospital-based study
Xu et al. (2018)13

Author (Year)

TA B L E 4 (Continued)

Title

Study type

Sample characteristics

were presented (Table 3). Ferenci and colleagues clearly defined the

sample set, the authors supported the 4 μmol/g cutoff, with 99.4%
sensitivity and 96.1% specificity.18 Yang and authors had a larger

sample size as compared to the former studies and clearly defined
the criteria and methodology of the adult sample included.18 Minute
differences may exist because distinct methodologies may also reflect ethnic and racial differences in alleles causing disease in the
populations. Both Sezer and Nicastro tested hepatic copper using
different methodologies of flame atomic absorption spectroscopy in
the pediatric population with hepatic disease in Turkey and Italy, respectively.11,12 While Nicastro did not undertake a ROC analysis, the
authors used a 4 μmol/g cutoff based on the Leipzig criteria, yield-

ing a sensitivity of 65% and specificity of 77%.11 On the contrary,
Sezer noted that when the cutoff was decreased to a threshold of
1.5 μmol/g, the sensitivity increased to 91.4%, but the specificity

decreased to 65.8%.12

4

|

DISCUSSION

This systematic review assesses the clinical, biochemical, immunological, and genetic tests that are included in the heterogeneous
process of diagnosing WD. It may be stated that the variability in
optimal cutoff values according to ROC curve analysis depends on
the applied biochemical tests methodology and the age of participants as claimed by the evidence provided by the studies in this
review. Notably, EASL guidelines supply a narrative expert-base review about current evidence supporting the original Leipzig criteria.

|
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Cauza et al.19 conducted an assessment of 17 patients that had ce-

7 of 8

of the three tests for WD, we find that cutoffs are typically based

ruloplasmin levels less than 20 mg/dl. While only one asymptomatic

on the specific subgroups based on ethnicity, age, and clinical

patient had WD with no neurological signs of Kayser-Fleischer rings,

subgroups.

the other 16 patients were considered to be heterozygous carriers

While the findings of this systematic review may be used by the

of the WD gene. The positive predictive value of low ceruloplasmin

readers, and despite the included studies employing the Leipzig WD

was merely 5.9%. Despite considerations regarding the measure-

criteria, some of the included studies had limited details about the

ment of hepatic copper content as the gold standard for diagnosing

methodologies and the calculations, despite mentioning the index

WD, Ferenci and colleagues, in one of the largest studies in this area,

tests being appraised. While the current literature addresses the

highlight the occurrence of false-negative results due to sampling

possible gold standards to diagnose WD, there is a lack of disease

17

errors or differences in hepatic copper distribution.

Nine studies, including a total of 5,762 participants (which com-

definition and there is a poorly defined index test methodology.
Moreover, while ceruloplasmin levels are helpful in diagnosing WD,

prised of 1,163 individuals with Wilson's disease) were assessed.

the feasibility and cost-effectiveness of utilizing serum ceruloplas-

Three studies involved the pediatric population only, one comprised

min in presymptomatic WD may be low.19 With these limitations

of adults only, and the other five studies involved both adult and

in mind, we believe that the methodological weaknesses of the in-

pediatric populations. Two studies assessed individuals with hepatic

cluded studies may have resulted in overestimation of the accuracy

signs only, and the other seven studies assessed the combination of

of the index tests, despite still offering pertinent information to

neurological and hepatic signs and symptoms of WD. There were

medical communities worldwide.

variable methodological qualities of the studies, the risk of bias
due to the study types was documented, and the key differences

AC K N OW L E D G E M E N T S

in assays and cutoff values for the diagnostic tests are enlisted in

None.

Tables 1–4.
When noting the ceruloplasmin index test, a total of five studies assessed the thresholds, pooling in 4,281 individuals with 541

C O N FL I C T O F I N T E R E S T
None.

confirmed WD patients. The all-around scalable cutoff value was
found to be ranging from 0.14 to 0.2 g/L. When using a cutoff

DATA AVA I L A B I L I T Y S TAT E M E N T

of 0.2 g/L as per the Leipzig criteria, a sensitivity of 77.1%–99%

All data used and acquired for this study are available online.

was achieved and the specificity ranged from 55.9% to 82.8%. On
noting the 0.1 g/L cutoff as per the Leipzig criteria, the sensitivity

ORCID

ranged from 65% to 78.9%, whereas the specificity ranged from

Zouina Sarfraz

96.6% to 100%. The best practice guidelines resonate that a highly

Azza Sarfraz

sensitive test leads to fewer false-n egative results, and fewer WD
cases are missed, whereas the specificity of the ceruloplasmin
test means that there are fewer false-p ositive results. The most
scalable test result has maximum sensitivity and specificity. While
the current literature states that the ceruloplasmin level for WD
will probably be below 0.1 g/L, our synthesis identifies, 20 based
on the data obtained by five studies, the optimal cutoff for the
ceruloplasmin index test was determined to be between 0.14 and
0.2 g/L.
The 24-hour urinary copper test was evaluated based on three
studies, and there were varying thresholds using a participant
size of 268, with 101 confirmed WD patients. While EASL posts
1.6 μmol/24 h as the cutoff, we found that the best practice evidence suggests a cutoff ranging from 0.64 to 1.6 μmol/24 h based
on the Leipzig criteria, which achieves a sensitivity vs. specificity of
50% vs. 80% and 75.6% vs. 98.3%, respectively.
The hepatic copper test assessed a total of 1150 individuals with
367 WD patients. The hepatic cutoff in the Leipzig criteria achieved
a sensitivity of 65.7%–94.4% and specificity of 52.2%–98.6%.
Overall, the cutoffs for ceruloplasmin, 24-hour urinary copper,
and hepatic copper test are reliant on the methodologies adopted
by the testing facility and do require validation in the population
when the index tests are used at large. While we provide cutoffs

https://orcid.org/0000-0002-5132-7455
https://orcid.org/0000-0001-8206-5745
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